TriLogic Pharma is a specialty pharmaceutical company that has developed a proprietary drug delivery platform capable of delivering a large number of active compounds.  The platform, TRI-726, can deliver an active compound from several hours to several days.

TriLogics focus is in veterinary medicine for its drug delivery platform, which is liquid at room temperature but gels when placed in the body and is naturally eliminated over time.

Our immediate commitment to our shareholders is to maximize our existing drug delivery platform through innovative and effective products. Our long term commitment is to help solve tomorrows drug delivery needs by continually creating better delivery technologies.

Trilogic Pharma -- working on clear solutions for innovative drug delivery.

  • 08.06.2013
  • TriLogic Pharma announced today that it received an Issue Notification from the United States Patent and Trademark Office (USPTO) for its patent application covering TRI-726, its sustained release, self solidifying, bioeroding, drug delivery platform.

    read more

  • 09.19.2011
  • TriLogic Pharma’s Chief Scientific Officer, Hemant H. Alur, PhD, MBA, will be speaking at the Partnership Opportunities in Drug Delivery conference to be held October 4-5, 2011, in Boston, MA..

    read more

  • 01.10.2011
  • TriLogic Pharma Chief Scientific Officer to speak at Pharmaceutical Risk and Research Europe. TriLogic Pharma announced that Chief Scientific Officer Hemant H. Alur, PhD, MBA has been invited to speak at the Pharmaceutical Risk and Research Europe Conference in London on March 24th. Dr. Alur will present TriLogic Pharma’s novel drug delivery platform, TRI-726.

    read more